MNG915
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.465
- ALLOGRAFT_REJECTION+0.419
- PANCREAS_BETA_CELLS+0.372
- MYOGENESIS+0.270
- COAGULATION+0.242
- KRAS_SIGNALING_UP+0.242
- UV_RESPONSE_DN+0.237
- IL6_JAK_STAT3_SIGNALING+0.233
- KRAS_SIGNALING_DN+0.230
- INTERFERON_GAMMA_RESPONSE+0.225
Top 10 suppressed
- G2M_CHECKPOINT-0.456
- MYC_TARGETS_V2-0.440
- E2F_TARGETS-0.438
- DNA_REPAIR-0.396
- MITOTIC_SPINDLE-0.353
- MYC_TARGETS_V1-0.341
- MTORC1_SIGNALING-0.295
- CHOLESTEROL_HOMEOSTASIS-0.261
- TNFA_SIGNALING_VIA_NFKB-0.234
- UV_RESPONSE_UP-0.221
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0747 | Med | Medulloblastoma | 0.892 |
| 2 | MNG929 | — | — | 0.886 |
| 3 | 20040019.LumA | — | A | 0.881 |
| 4 | SRR26320092 | — | — | 0.868 |
| 5 | SRR2665516 | — | — | 0.865 |
| 6 | SRR1467011 | GTEX | — | 0.858 |
| 7 | SRR8518299 | — | A | 0.858 |
| 8 | ERR2208964 | — | — | 0.854 |
| 9 | TCGA-55-8621-01A-11R-2403-07 | — | cohortA1 | 0.851 |
| 10 | SRR23303748 | — | — | 0.848 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.465 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.419 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.372 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.270 | Inavolisib | — uncovered |
| COAGULATION | 0.242 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.242 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.237 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.233 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.230 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.225 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.185 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.181 | Temsirolimus | — uncovered |
| HYPOXIA | 0.147 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.144 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.113 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.108 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.103 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.091 | Idelalisib | — uncovered |
| COMPLEMENT | 0.065 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.037 | Inavolisib | — uncovered |